Whanin Pharmaceutical (016580): the quiet leader in psychiatric drugs — why profit collapsed, and whether the rebound is real
Korea’s number one psychiatric drug maker saw its operating margin erode from 17.6% to 5.1% over five years, then posted a sharp rebound in Q1 2026. Two scenarios, with thresholds set in advance.